Pharma Mar SA (ES:PHM) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Pharma Mar SA has successfully recruited 705 patients for its phase III LAGOON clinical trial, which evaluates the efficacy of Zepzelca® (lurbinectedin) in treating small cell lung cancer. This significant milestone reflects the company’s ongoing commitment to expanding treatment options, with preliminary results anticipated in early 2026. The trial aims to assess overall and progression-free survival, contributing to the growing body of research on advanced cancer therapies.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
